Compare MLYS & WLDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLYS | WLDN |
|---|---|---|
| Founded | 2019 | 1964 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.2B |
| IPO Year | 2023 | 2006 |
| Metric | MLYS | WLDN |
|---|---|---|
| Price | $26.00 | $88.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $48.67 | ★ $114.50 |
| AVG Volume (30 Days) | ★ 880.6K | 504.3K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 37.43 | ★ 120.89 |
| EPS | N/A | ★ 0.55 |
| Revenue | N/A | ★ $273,352,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.05 |
| P/E Ratio | ★ N/A | $162.40 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.59 | $49.75 |
| 52 Week High | $47.65 | $137.00 |
| Indicator | MLYS | WLDN |
|---|---|---|
| Relative Strength Index (RSI) | 40.36 | 57.89 |
| Support Level | $25.16 | $74.08 |
| Resistance Level | $31.12 | $99.61 |
| Average True Range (ATR) | 1.58 | 5.47 |
| MACD | -0.36 | 1.49 |
| Stochastic Oscillator | 6.90 | 64.85 |
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
Willdan Group Inc is a provider of professional technical and consulting services to utilities, private industry, and public agencies at all levels of government. It operates in the business segments of Energy and Engineering and Consulting. It generates the majority of its revenue from the Energy segment, which includes services such as audit and surveys, program design, master planning, benchmarking analysis, design engineering, construction management, performance contracting, installation, advances in software and data analytics, and other services. All of its revenue is derived from the domestic markets.